The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 943-955

  Mohammed, Zahra M A ^a   Going, James J ^a   Edwards, Joanne ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; Immune cells; Recurrence and survival; Tumour inflammatory infiltrate

Indexed keywords

CD45RO ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

B LYMPHOCYTE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CYTOTOXICITY; FOLLOW UP; HUMAN; INFLAMMATORY CELL; MAST CELL; METHODOLOGY; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; VALIDATION STUDY;

BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 84867143726     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.04.011     Document Type: Review

References (70)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94(2):153-156.
2. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin 1999, 49(1):33-64.
3. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
5. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
6. Roxburgh C.S., McMillan D.C. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012, 38(5):451-466.
7. Pierce B.L., Ballard-Barbash R., Bernstein L., Baumgartner R.N., Neuhouser M.L., et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009, 27(21):3437-3444.
8. Roxburgh C.S.D., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6(1):149-163.
9. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., Fletcher C.D., et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011, 47(17):2633-2641.
10. Allin K.H., Nordestgaard B.G., Flyger H., Bojesen S.E. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 2011, 13(3):R55.
11. Underwood J.C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 1974, 30(6):538-548.
12. Stewart T.H., Tsai S.C. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis 1993, 11(4):295-305.
13. Alderson M.R., Hamlin I., Staunton M.D. The relative significance of prognostic factors in breast carcinoma. Br J Cancer 1971, 25(4):646-656.
14. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V.M., Marin S., et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992, 28A(4-5):859-864.
15. Alexe G., Dalgin G.S., Scanfeld D., Tamayo P., Mesirov J.P., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007, 67(22):76-10669.
16. Bloom H.J., Richardson W.W., Field J.R. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1411 cases of breast cancer followed for 20years. Br Med J 1970, 3(5716):181-188.
17. Cutler S.J., Black M.M., Mork T., Harvei S., Freeman C. Further observations on prognostic factors in cancer of the female breast. Cancer 1969, 24(4):653-667.
18. Dipaola M., Angelini L., Bertolot A., Colizza S. Host resistance in relation to survival in breast-cancer. Br Med J 1974, 4(5939):268-270.
19. Hamlin I.M. Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer 1968, 22(3):383-401.
20. Lee A.H.S., Gillett C.E., Ryder K., Fentiman I.S., Miles D.W., et al. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 2006, 48(6):692-701.
21. Pupa S.M., Bufalino R., Invernizzi A.M., Andreola S., Rilke F., et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996, 14(1):85-94.
22. Rakha E.A., Aleskandarany M., El Sayed M.E., Blamey R.W., Elston C.W., et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009 July, 45(10):1780-1787.
23. Ridolfi R.L., Rosen P.P., Port A., Kinne D., Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977, 40(4):1365-1385.
24. Rilke F., Colnaghi M.I., Cascinelli N., Andreola S., Baldini M.T., et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991, 49(1):44-49.
25. Menard S., Tomasic G., Casalini P., Balsari A., Pilotti S., et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997, 3(5):817-819.
26. Elston C.W., Gresham G.A., Rao G.S., Zebro T., Haybittle J.L., et al. The cancer-research campaign (Kings Cambridge) trial for early breast-cancer - clinicopathological aspects. Br J Cancer 1982, 45(5):655-669.
27. Haybittle J.L., Blamey R.W., Elston C.W., Johnson J., Doyle P.J., et al. A prognostic index in primary breast cancer. Br J Cancer 1982, 45(3):361-366.
28. Richardson W.W. Medullary carcinoma of the breast - a distinctive tumour type with a relatively good prognosis following radical mastectomy. Br J Cancer 1956, 10(3):415.
29. White W.C. Late results of operation for carcinoma of the breast. Ann Surg 1927, 86(5):695-701.
30. Carlomagno C., Perrone F., Lauria R., de Laurentiis M., Gallo C., et al. Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 1995, 52(4):272-277.
31. Champion H.R., Wallace I.W., Prescott R.J. Histology in breast cancer prognosis. Br J Cancer 1972, 26(2):129-138.
32. Fisher E.R., Kotwal N., Hermann C., Fisher B. Types of tumor lymphoid response and sinus histiocytosis - relationship to 5-year, disease-free survival in patients with breast-cancer. Arch Pathol Lab Med 1983, 107(5):222-227.
33. Holmberg L., Adami H.O., Lindgren A., Ekbom A., Sandström A., et al. Prognostic significance of the Ackerman classification and other histopathological characteristics in breast cancer. An analysis of 1349 consecutive cases with complete follow-up over seven years. APMIS 1988, 96(11):979-990.
34. Rosen P.P., Saigo P.E., Braun D.W., Weathers E., DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg 1981, 193(1):15-25.
35. Rosen P.P., Saigo P.E., Braun D.W., Weathers E., Kinne D.W. Prognosis in stage II (T1N1M0) breast cancer. Ann Surg 1981, 194(5):576-584.
36. Rosen P.P., Groshen S. Factors influencing survival and prognosis in early breast-carcinoma (T1N0M0-T1N1M0) - assessment of 644 patients with median follow-up of 18 years. Surg Clin NA 1990, 70(4):937-962.
37. Calabro A., Beissbarth T., Kuner R., Stojanov M., Benner A., et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 2009, 116(1):69-77.
38. Chin Y., Janseens J., Vandepitte J., Vandenbrande J., Opdebeek L., et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1992, 12(5):1463-1466.
39. Treilleux I., Blay J.Y., Bendriss-Vermare N., Ray-Coquard I., Bachelot T., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004, 10(22):7466-7474.
40. Schmidt M., Bãhm D., Von Tãrne C., Steiner E., Puhl A., et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68(13):5405-5413.
41. Rody A., Holtrich U., Pusztai L., Liedtke C., Gaetje R., et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009, 11(2):R15.
42. Al Murri A.M., Hilmy M., Bell J., Wilson C., McNicol A.M., et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 2008, 99(7):1013-1019.
43. Mahmoud S.M.A., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H.S., et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011, 127(1):99-108.
44. Ladoire S., Mignot G., Dabakuyo S., Arnould L., Apetoh L., et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011, 224(3):389-400.
45. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24(34):5373-5380.
46. de Kruijf E.M., van Nes J.G.H., Sajet A., Tummers Q.R.J.G., Putter H., et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010, 16(4):1272-1280.
47. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69(5):2000-2009.
48. Liu F., Lang R., Zhao J., Zhang X., Pringle G.A., et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011, 130(2):645-655.
49. Yan M., Jene N., Byrne D., Millar E.K., O'Toole S.A., et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011, 13(2):R47.
50. Scholl S.M., Pallud C., Beuvon F., Hacene K., Stanley E.R., et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Nat Cancer Inst 1994, 86(2):120-126.
51. Scholl S.B. Relevance of multiple biological parameters in breast cancer prognosis. Breast 1996, 5:21-30.
52. Baker K., Lachapelle J., Zlobec I., Bismar T.A., Terracciano L., et al. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011, 58(7):1107-1116.
53. Mahmoud S.M.A., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29(15):1949-1955.
54. Mahmoud S.M.A., Lee A.H.S., Paish E.C., Macmillan R.D., Ellis I.O., et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2011, (1).
55. Campbell M.J., Tonlaar N.Y., Garwood E.R., Huo D., Moore D.H., et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011, 128(3):703-711.
56. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1(1):54-67.
57. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
58. Shabo I., Stål O., Olsson H., Doré S., Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 2008, 123(4):780-786.
59. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005, 14(2):425-431.
60. Volodko N., Reiner A., Rudas R., Jakesz R. Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 1998, 7(2):99-105.
61. Kobayashi H., Ishizuka T., Okayama Y. Human mast cells and basophils as sources of cytokines. Clin Exp Allergy 2000, 30(9):1205-1212.
62. Aaltomaa S., Lipponen P., Papinaho S., Kosma V.M. Mast cells in breast cancer. Anticancer Res 1993, 13(3):785-788.
63. Amini R.M., Aaltonen K., Nevanlinna H., Carvalho R., Salonen L., et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007, 7:165.
64. Dabiri S., Huntsman D., Makretsov N., Cheang M., Gilks B., et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004, 17(6):690-695.
65. Rajput A.B., Turbin D.A., Cheang M.C., Voduc D.K., Leung S., et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4444 cases. Breast Cancer Res Treat 2008, 107(2):249-257.
66. Vanderslice P., Ballinger S.M., Tam E.K., Goldstein S.M., Craik C.S., et al. Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Nat Acad Sci USA 1990, 87(10):3811-3815.
67. Miettinen M., Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005, 13(3):205-220.
68. Berg J.W. Inflammation and prognosis in breast cancer; a search for host resistance. Cancer 1959, 12(4):714-720.
69. Iwamoto M., Shinohara H., Miyamoto A., Okuzawa M., Mabuchi H., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003, 104(1):92-97.
70. Lespagnard L., Gancberg D., Rouas G., Leclercq G., Saint-Aubain S.N., et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999, 84(3):309-314.